4 Clinical potential of low molecular weight heparins

Bailliere's Clinical Haematology

Volumn 3, Issue 3, 1990, Pages 545-554

  Levine, Mark N ^a   Hirsh, Jack ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADOLESCENT; ADULT; BLOOD CLOTTING; CASE REPORT; FEMALE; HEART SURGERY; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

COMPARATIVE STUDY; FACTOR XA; HEMORRHAGIC DISORDERS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; THROMBOPHLEBITIS;

EID: 0025163643     PISSN: 09503536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3536(05)80018-6     Document Type: Article

References (37)

1. A new low molecular weight heparin derivative, in vitro and in vivo studies
2. Comparative pharmacokinetics of a low molecular weight heparin (PK10169) and unfractionated heparin after intravenous and subcutaneous administration
3. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
4. Prophylaxis against post-operative deep vein thrombosis—a double-blind multicentre trial comparing a heparin fragment given on the evening before surgery with conventional low dose heparin
5. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit
6. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment
7. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
8. Early clinical experience of a new heparinoid, ORG10172, in prevention of deep venous thrombosis
9. The relationship between the hemorrhagic antithrombotic properties of low molecular weight heparin in rabbits
10. From heparin to heparin fractions and derivatives
11. Treatment of proximal deep vein thrombosis of the lower limbs by CY216 (LMWH) versus unfractionated heparin (UFH)
12. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
13. Subcutaneous administration of a low molecular weight heparin (CY222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis
14. Heparin, its fractions, fragments and derivatives
15. Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight
16. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect
17. Efficacy and safety of a low molecular weight heparin in prophylaxis of postoperative deep vein thrombosis after gynecologic surgery
18. Bioavailability and antagonization of the low molecular weight heparin CY216 in man
19. The development of low molecular weight heparins for clinical use
20. Prevention of deep vein thrombosis (DVT) following total hip replacement by a low molecular weight heparinoid (ORG 10172)
21. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin
22. Efficacy and safety of low molecular weight heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study
23. Low molecular weight heparin (KABI-2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin
24. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement
25. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction
26. Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement
27. Prevention of deep vein thrombosis after total hip replacement by enoxaparine: one daily injection of 40 mg versus two daily injections of 20 mg
28. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement
29. Thrombosis prophylaxis with low molecular weight heparin (KABI 2165) and calcium heparin in patients with total hip replacement
30. Deep vein thrombosis prophylaxis with a low molecular weight heparin (Kabi 2165) in stroke patients
31. Low molecular weight heparin (enoxaparine) compared with unfractionated heparin thrice a day in prevention of postoperative thrombosis
32. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis
33. Randomized double-blind, placebo controlled safety study of low molecular weight heparinoid in patients undergoing transurethral resection of the prostate
34. A randomized controlled trial of low molecular weight heparin (enoxaparine) to prevent deep vein thrombosis in patients undergoing elective hip surgery
35. A double-blind randomized trial of ORG10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in thrombotic stroke
36. Efficacy and safety of a low molecular weight heparin (LMW-heparin Sandoz) in patients with deep vein thrombosis